(Q53495126)

1 July 2019

title

The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research. (English)

1 reference

1 July 2019

1

Halina Ostrowska

1 reference

1 July 2019

publication date

29 February 2008

1 reference

1 July 2019

Cellular & Molecular Biology Letters

published in

1 reference

1 July 2019

volume

13

1 reference

1 July 2019

issue

3

1 reference

1 July 2019

page(s)

353-365

1 reference

1 July 2019

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

cites work

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

A giant protease with potential to substitute for some functions of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Ubiquitin-proteasome system and proteasome inhibition: new strategies in stroke therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

The p53-Mdm2 module and the ubiquitin system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

The ubiquitin system: pathogenesis of human diseases and drug targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

E3 ubiquitin ligases as cancer targets and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Nuclear factor-kappaB in cancer development and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Proteasome inhibition attenuates infarct size and preserves cardiac function in a murine model of myocardial ischemia-reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Drug discovery in the ubiquitin-proteasome system.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Proteasome inhibition as novel treatment strategy in leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Proteasome and peptidase function in MHC-class-I-mediated antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

The proteasome and proteasome inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Early clinical experience with the novel proteasome inhibitor PS-519.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Delayed treatment of ischemia/reperfusion brain injury: extended therapeutic window with the proteosome inhibitor MLN519.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Development of the proteasome inhibitor Velcade (Bortezomib).

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Targeted protein degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Series introduction: the transcription factor NF-kappaB and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

LMP2-specific inhibitors: chemical genetic tools for proteasome biology

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Proteasome inhibitors as new anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Proteasome inhibitors: from research tools to drug candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

A small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Neuroprotection with the proteasome inhibitor MLN519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

The ubiquitin proteasome pathway from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.2478%2FS11658-008-0008-7

Skp2 is oncogenic and overexpressed in human cancers

21 January 2018

1 reference

12 December 2020

Pathophysiological role of proteasome-dependent proteolytic pathway in endothelin-1-related cardiovascular diseases

1 reference

12 December 2020

Proteasome inhibitors as therapeutic agents: current and future strategies.

1 reference

12 December 2020

Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury

1 reference

12 December 2020

Proteasome inhibition: a new anti-inflammatory strategy

1 reference

12 December 2020

Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme

1 reference

12 December 2020

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

1 reference

12 December 2020

Preventive effect of lactacystin, a selective proteasome inhibitor, on ischemic acute renal failure in rats.

1 reference

12 December 2020

Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia

1 reference

12 December 2020

Nuclear factor kappaB mediates a procoagulant response in monocytes during extracorporeal circulation

1 reference

12 December 2020

Proteasome inhibitor drugs on the rise

1 reference

12 December 2020

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

1 reference

12 December 2020

Degradation of target protein in living cells by small-molecule proteolysis inducer

1 reference

12 December 2020

Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats

1 reference

12 December 2020

Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart

1 reference

12 December 2020

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

1 reference

12 December 2020

MLN-519. Millennium/PAION

1 reference

12 December 2020

10.2478/S11658-008-0008-7

Identifiers

DOI

1 reference

1 July 2019

Dimensions Publication ID

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.2478/s11658-008-0008-7

PMC publication ID

6275582

1 reference

1 July 2019

PubMed publication ID

18311545

1 reference

1 July 2019